Phathom Pharmaceuticals to Share VOQUEZNA Data at ACG 2024 Annual Meeting
Description:
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD), for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn, and in combination with antibiotics for the eradication of Helicobacter pylori (H. pylori) infection. VOQUEZNA is the first and only U.S. Food and Drug Administration (FDA)-approved potassium-competitive acid blocker (PCAB).
Impact on Individuals:
For individuals suffering from gastrointestinal diseases like GERD and Erosive Esophagitis, the availability of VOQUEZNA as a treatment option can be life-changing. This innovative medication offers relief from symptoms such as heartburn and can aid in the eradication of infections like H. pylori, improving overall health and quality of life for patients.
Impact on the World:
The presentation of data on VOQUEZNA at the ACG 2024 Annual Meeting signifies a significant advancement in the field of gastroenterology. The introduction of a novel treatment like VOQUEZNA showcases the continuous innovation and development in the pharmaceutical industry towards combating GI diseases, ultimately leading to improved healthcare outcomes on a global scale.
Conclusion:
Phathom Pharmaceuticals’ sharing of VOQUEZNA data at the ACG 2024 Annual Meeting highlights the company’s commitment to advancing treatment options for GI diseases. The approval and availability of this first-in-class medication offer hope for individuals struggling with conditions like GERD and Erosive Esophagitis, while also contributing to the broader progress in the healthcare industry worldwide.
